Share

FDA Approves First Treatment for Thyroid Eye Disease

In January, Endocrine News reported on the possible upcoming availability of teprotumumab as a promising treatment for of thyroid eye disease (TED), a serious, progressive and vision-threatening rare autoimmune disease that is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain, inflammation, and facial disfigurement. Up to 50% of patients with Graves’ disease...
Share

Older Adults with Hypothyroidism Face Elevated Risk of Death

Increased risk does not impact older adults with subclinical hypothyroidism While older adults with hypothyroidism face an elevated risk of death, individuals with subclinical hypothyroidism, a milder form of underactive thyroid, did not face the same risk, according to new research published in The Journal of Clinical Endocrinology & Metabolism. “Our meta-analysis is the first to...
Share

Slightly Elevated TSH Levels Not a Cause for Referral to Pediatric Endocrinologists

Children with thyroid stimulating hormone (TSH) levels slightly above reference range shouldn’t be referred to pediatric endocrinologists unless there is another cause for clinical concern, according to a paper recently published in the Journal of the Endocrine Society. Researchers led by Perrin C. White, MD, of the Division of Pediatric Endocrinology at the University of...
Share

New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meeting

New pooled data from the Phase 2 and Phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oct. 31. The U.S. Food and Drug Administration is currently evaluating...
Share

Researchers Identify Role of ATP-Binding Cassette Transporters in Anaplastic Thyroid Cancer Resistance to Chemotherapy

ATP-binding cassette (ABC) transporters are the major determinants of anaplastic thyroid cancer (ATC) resistance to chemotherapy, and these transporters could be key in tailoring treatments for patients with ATC, according to a paper recently published in Endocrinology. Researchers led by Vahid Haghpanah, MD, MPH, PhD, of the Endocrinology and Metabolism Research at the Tehran University...
Share

Takeda Announces NATPARA Special Use Program in the U.S.

In the wake of the recall of hypoparathyroidism drug NATPARA, the drug’s manufacturer, Takeda, is working with the FDA to develop a Special Use Program. The program is intended to support patients previously prescribed NATPARA who are facing life-threatening complications as a result of discontinuation of NATPARA. Through this program, healthcare providers will be able...

Endocrine News provides the latest news and research articles on thyroid conditions and treatment. For more info read this month’s issue of Endocrine News.